Saama and Pfizer to Transform Work of Clinical Data Managers and Monitors With AI

Saama Logo

Campbell, CA (February 18, 2020) - Saama Technologies, Inc., the number one AI clinical analytics platform company, announced today that it signed an agreement with Pfizer Inc. to develop and deploy an AI-powered analytics solution to reduce the challenges commonly experienced by clinical study data managers and monitors. Under this agreement, Saama’s award-winning Life Science Analytics Cloud (LSAC) platform will aggregate, transform, analyze, model and predict clinical data queries using deep learning techniques. Pfizer will provide the required ground truth clinical data and domain expertise to train Saama models to achieve the required accuracy.

“Saama is pioneering transformational changes to the way clinical study data is managed and understood by pharma, since current processes and systems are mostly manual and take a significant amount of time,” said Sagar Anisingaraju, Chief Strategy Officer, Saama Technologies. “As part of this collaboration with Pfizer, the deep learning models of LSAC will be further trained and improved to provide augmented intelligence, empowering data managers to operate more efficiently and effectively. Saama appreciates the leadership role that Pfizer is taking to solve this industry-wide problem by providing valuable clinical data across therapeutic areas for training our smart data query solution.”

“Historically, our industry has been limited to manual, inefficient data review processes to validate data from our clinical trials,” said Demetris Zambas, Pfizer Vice President and Head of Data Monitoring and Management. “Through our strategic collaboration with Saama Technologies, we’ve identified efficiencies to improve processes and experiences for our clinical research partners.”

About LSAC

Life Science Analytics Cloud (LSAC) is the leading AI-powered clinical analytics platform that seamlessly integrates, curates, and animates clinical trial data, delivering more actionable insights.

About Saama Technologies, Inc.

Saama is the number one AI clinical analytics platform company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs. Ten of the top 20 pharmaceutical companies use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform. LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. Discover more at and follow Saama @SaamaTechInc.

About Carrick Capital Partners
Who We Are
A firm of enterprise software, SaaS, and technology enabled services investors and operating executives with substantial experience founding, scaling, and optimizing market leading businesses.
Our Approach
We work with management to identify and improve critical areas of their business - focusing on the priorities that align with our experiences and that will deliver the highest strategic impact in both the short-term and long-run.
Why We Are Different
We have a concentrated number of companies in our portfolio so that we can build substantial relationships with each management team and ensure our firm's commitment to each company's goals.
Latest News
Infrascale Logo.jpg
C-Level Executives’ Primary Data Protection Concerns Diverge By Sector – Data Security and Encryption Are Most Important in Legal, Data Backup and Recovery Are Top Priority in Education
March 31, 2020
Complia Logo.jpg
Complia Health and the Interim HealthCare franchise network continue a close, longstanding partnership and have extended a many-year agreement following a decade of proven success.
March 5, 2020
Accolade Logo.jpg
Seattle, WA (February 28, 2020) – Accolade, Inc. (“Accolade”), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Accolade intends to list its common stock on the Nasdaq Global Select Market under the ticker symbol ACCD.
February 28, 2020